Please assess the completion status of the following clinical trial:

Trial Title: Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Male or non-pregnant, non-lactating female subjects Diagnosed with IBS confirmed by the Rome III criteria~Meet the following IBS symptom scores in all categories during the diary eligibility period:~* An average daily score of greater than or equal to 3 for abdominal pain~* An average daily score of greater than or equal to 3 for bloating~* An average daily score of 5 or greater for stool consistency using the Bristol Stool Scale~* Does not have adequate relief of IBS symptoms (weekly reported) over the past 7 days on the first day of screening and on the day of randomization~Exclusion Criteria:~* Present with hard or lumpy stools (Type 1 or Type 2) on the Bristol Stool form Scale during the diary eligibility period~* history of inflammatory bowel disease~* has Type 1 or 2 diabetes~* pregnant or lactating~* history of HIV or hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Mesalamine Granules 750 mg (Type: EXPERIMENTAL): None
- Mesalamine Granules 1500 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).